Table 3:

Personal history of autoimmune disease and risk of progression of MGUS to LP and MM

				LP✣			MM✣✣
	Total (n=19,303)	No progression (n= 16,952)	Progression (n=2,351)	HR✣✣✣	95% CI✣✣✣✣	p value	HR	95% CI	p value
Autoantibodies detectable	3,731	3,355	376	0.73	0.61–0.86	0.0002	0.75	0.61–0.93	0.0079
Systemic involvement	1,271	1,152	119	0.67	0.51–0.88	0.0037	0.63	0.45–0.88	0.0077
Rheumatoid arthritis	979	886	93	0.66	0.48–0.91	0.0114	0.72	0.50–1.05	0.0870
Sjögren syndrome	225	198	27	1.20	0.74–1.94	0.4581	0.70	0.33–1.45	0.3297
Organ involvement	2,720	2,445	275	0.73	0.59–0.90	0.0034	0.80	0.62–1.03	0,0823
Autoimmune hemolytic anemia	125	106	19	1.04	0.43–2.51	0.9227	0.62	0.16–2.49	0,5005
Chronic rheumatic heart disease	169	153	16	0.49	0.20–1.17	0.1084	0.76	0.32–1.84	0.5478
Diabetes type I	1,621	1,461	160	0.85	0.62–1.17	0.3226	1.01	0.70–1.45	0.9607
Multiple sclerosis	70	61	9	0.82	0.45–1.48	0.4994	1.03	0.53–1.98	0.9307
Pernicious anemia	144	130	14	0.70	0.29–1.69	0.4298	1.09	0.45–2.64	0.8410
Autoantibodies not detectable	2,580	2,313	267	0.78	0.64–0.95	0.0116	0.69	0.54–0.89	0.0045
Aplastic anemia	188	153	35	1.21	0.50–2.92	0.6673	1.09	0.35–3.40	0.8772
Ankylosing spondylitis	118	105	13	0.41	0.15–1.10	0.0756	0.63	0.24–1.70	0.3626
Crohn’s disease	172	156	16	0.59	0.28–1.25	0.1693	0.64	0.27–1.54	0.3172
Temporal arteritis	354	310	44	1.05	0.67–1.63	0.8331	0.86	0.47–1.55	0.6111
Polymyalgia rheumatica	1,052	956	96	0.87	0.66–1.15	0.3378	0.78	0.54–1.12	0.1735
Psoriatic arthritis	177	167	10	0.79	0.35–1.76	0.5589	0.57	0.18–1.78	0.3367
Sarcoidosis	144	134	10	0.52	0.25–1.08	0.0799	0.45	0.17–1.21	0.1133
Ulcerative cholitis	256	229	27	0.90	0.53–1.52	0.6918	0.97	0.52–1.80	0.9153

^✣Lymphoproliferative disease

^✣✣Multiple myeloma

^✣✣✣Hazard ratio, adjusted for age, gender and year of diagnosis

^✣✣✣✣CI denotes confidence interval